1
|
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Rossi D, Dirnhofer S, Ceriani L, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.78_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Stathis
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - U. Mey
- Oncology and Hematology; Kantonsspital Graubuenden; Chur Switzerland
| | - S. Schär
- Coordinating Center; SAKK; Bern Switzerland
| | - F. Hitz
- Oncology/Hematology; Kantonsspital St.Gallen; St.Gallen Switzerland
| | - C. Pott
- Medizinischen Klinik II Hämatologie und Internistische Onkologie; Universitätsklinikum Schleswig-Holstein; Campus Kiel Kiel Germany
| | - N. Mach
- Service d'Oncologie; Département d'Oncologie, Hôpitaux Universitaires de Genève; Genève Switzerland
| | - F. Krasniqi
- Medical Oncology; University Hospital of Basel; Basel Switzerland
| | - U. Novak
- Department of Medical Oncology; Inselspital / Bern University Hospital; Bern Switzerland
| | - C. Schmidt
- Department of Medicine III; University of Munich; Munich Germany
| | - K. Hohloch
- Oncology and Hematology; Kantonsspital Graubuenden; Chur Switzerland
| | - D. Kienle
- Oncology and Hematology; Kantonsspital Graubuenden; Chur Switzerland
| | - D. Hess
- Oncology/Hematology; Kantonsspital St.Gallen; St.Gallen Switzerland
| | - A. Moccia
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Unterhalt
- Department of Medicine III; University of Munich; Munich Germany
| | | | - S. Hayoz
- Coordinating Center; SAKK; Bern Switzerland
| | - D. Rossi
- Laboratory of Experimental Hematology; Institute of Oncology Research; Bellinzona Switzerland
| | - S. Dirnhofer
- Pathologie; Universitätsspital Basel; Basel Switzerland
| | - L. Ceriani
- Nuclear Medicine and PET-CT centre; Imaging Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Bertoni
- Lymphoma Genomics; Institute of Oncology Research; Bellinzona Switzerland
| | - C. Buske
- CCC Ulm; University Hospital Ulm; Ulm Germany
| | - E. Zucca
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - W. Hiddemann
- Department of Medicine III; University of Munich; Munich Germany
| |
Collapse
|
2
|
Zoellner A, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, Kluin-Nelemans H, Hiddemann W, Dreyling M, Hoster E. AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION-FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.13_2629] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Zoellner
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - M. Unterhalt
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - S. Stilgenbauer
- Department of Internal Medicine I; University Hospital of Homburg; Homburg Germany
| | - K. Hübel
- Department of Medicine I; University Hospital of Cologne; Cologne Germany
| | - C. Thieblemont
- Hemato-Oncology Department; Diderot University; Hôpital Saint-Louis Paris France
| | - B. Metzner
- Department of Hematology/Oncology; University Hospital Oldenburg; Oldenburg Germany
| | | | - W. Hiddemann
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - M. Dreyling
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - E. Hoster
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| |
Collapse
|
3
|
Ammon A, Weber MH, Wallner I, Marschner N, Droese M, Gröne HJ, Hiddemann W. Expression of the Tumor-Associated Glycoproteins Mca, Ca 125 and Bw 495/36-P in Epithelial Tumors of the Kidney and the Urinary Bladder. Int J Biol Markers 2018; 9:224-30. [PMID: 7836800 DOI: 10.1177/172460089400900404] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The differential expression of the tumor-associated glycoproteins MCA, CA 125 and BW 495/36-P was investigated in 11 renal cell carcinomas and 11 urinary bladder carcinomas and compared with their expression in non-neoplastic tissue preparations from the kidney (n = 9) and urinary bladder (n = 12). The glycoproteins were demonstrated immunohistologically in frozen sections and additionally, in some cases, in paraffin sections. MCA and BW 495/36-P positive cells were present in all preparations except for a grade I transitional cell carcinoma of the bladder, in which no MCA-expression could be detected. In the non-neoplastic renal tissue mainly the cells of the distal tubuli were stained by the antibodies against these two glycoproteins. Carcinoma cells of the kidney and of the urinary bladder showed an increased expression of both epitopes. CA 125, in comparison, was strongly expressed in 3 of the 11 urinary bladder carcinomas investigated but could only be shown in a few cells of a single renal cell carcinoma. Normal renal tissue showed no and the urinary bladder only very isolated CA 125 positive epithelial cells. Apart from this distribution, strong staining of the connective tissue fibers with CA 125 antibody was seen in all paraffin sections, but not in the frozen sections. This leads to the supposition that in these structures there is a CA 125 cryptantigen. The consistent expression of MCA as well as the virtual lack of CA 125 in the renal cell carcinomas are in contrast with our previous serological results, in which patients with metastatic renal cell carcinomas showed increased CA 125 in approx. 50% of cases whereas only approx. 20% had increased MCA serum levels.
Collapse
Affiliation(s)
- A Ammon
- Department of Hematology and Oncology, University of Göttingen, Germany
| | | | | | | | | | | | | |
Collapse
|
4
|
Ammon A, Weber MH, Wallner I, Marschner N, Droese M, Gröne HJ, Hiddemann W. Immunocytochemical determination of the tumor-associated glycoproteins MCA, CA 125 and BW 495/36-P in urine of patients with epithelial tumors of the kidney and urinary bladder. Int J Biol Markers 2018; 10:17-23. [PMID: 7629422 DOI: 10.1177/172460089501000104] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Pre-operative and, in some cases, post-operative urine samples from 29 patients with renal cell or urinary bladder carcinoma were compared to samples from 24 healthy persons and 10 patients with nephrolithiasis and 9 patients with other benign disorders of the efferent urinary tract. The specimens were examined for the presence of MCA, CA 125 and BW 495/36-P expressing epithelial cells. The urine concentrations of the soluble antigens MCA and CA 125 were determined simultaneously in urine samples from 35 patients with renal cell or urinary bladder carcinoma, 10 patients with cystitis and 30 healthy individuals. MCA and BW 495/36-P expressing epithelial cells were significantly increased in all pre-operative urine samples of the tumor patients compared to the group of healthy persons. This increase was also seen with CA 125-positive cells in patients with bladder carcinoma, not however in patients with renal cell carcinoma. BW 495/36-P positive cells were also found in both groups of tumor patients in greater numbers than in the patients with nephrolithiasis or other benign urinary tract disorders. Based on a specificity of 97% when compared to the control urine samples, the cytological determination of the antigens MCA, CA 125 and BW 495/36-P in urinary tract cells of all tumor patients revealed a sensitivity of 48%, 33% and 79% as well as a positive predictive value of 92%, 89% and 95%, respectively. The sensitivity of CA 125 increased to 67% upon isolated analysis of patients with bladder carcinoma. The majority of labelled cells were not identifiable as tumor cells morphologically and appeared as normal transitional epithelial cells. The urinary concentration of soluble MCA was greatest in healthy patients whereas the concentration of CA 125 was increased in patients with bladder carcinoma. Our results indicate that especially the determination of BW 495/36-P expressing epithelial cells could be a helpful supplement to the cytological examination of urinary epithelium with regard to renal cell and bladder carcinoma. Determination of CA 125-positive cells appears to be of diagnostic relevance only in cases of suspected bladder carcinoma.
Collapse
Affiliation(s)
- A Ammon
- Department of Hematology and Oncology, Urbachtal-Klinik, Neukirchen, Germany
| | | | | | | | | | | | | |
Collapse
|
5
|
Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, Metzeler KH, Dörfel D, Salih HR, Jung G, Nößner E, Jeremias I, Hiddemann W, Leonhardt H, Spiekermann K, Subklewe M, Greif PA. Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia 2018; 32:313-322. [PMID: 28895560 PMCID: PMC5808080 DOI: 10.1038/leu.2017.257] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Revised: 07/14/2017] [Accepted: 08/01/2017] [Indexed: 01/13/2023]
Abstract
The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in this setting as they are associated with unfavorable prognosis. Because of sequence-dependent protein conformational changes FLT3-ITD tends to autophosphorylate and displays a constitutive intracellular localization. Here, we analyzed the effect of tyrosine kinase inhibitors (TKIs) on the localization of the FLT3 receptor and its mutants. TKI treatment increased the surface expression through upregulation of FLT3 and glycosylation of FLT3-ITD and FLT3-D835Y mutants. In T cell-mediated cytotoxicity (TCMC) assays, using a bispecific FLT3 × CD3 antibody construct, the combination with TKI treatment increased TCMC in the FLT3-ITD-positive AML cell lines MOLM-13 and MV4-11, patient-derived xenograft cells and primary patient samples. Our findings provide the basis for rational combination of TKI and FLT3-directed immunotherapy with potential benefit for FLT3-ITD-positive AML patients.
Collapse
Affiliation(s)
- K Reiter
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - H Polzer
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - C Krupka
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
- Department of Translational Cancer Immunology, Gene Center Munich, LMU Munich, Munich, Germany
| | - A Maiser
- Department of BioIogy II, LMU Munich, Munich, Germany
| | - B Vick
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- Department of Gene Vectors, Helmholtz Zentrum München, German Research center for Enviromental Health, Munich, Germany
| | - M Rothenberg-Thurley
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - K H Metzeler
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - D Dörfel
- Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmology, Eberhard Karls Universität Tübingen, University Hospital Tübingen, Tübingen, Germany
- Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen, Tübingen, Germany
| | - H R Salih
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmology, Eberhard Karls Universität Tübingen, University Hospital Tübingen, Tübingen, Germany
- Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen, Tübingen, Germany
| | - G Jung
- Department of Immunology, Eberhard Karls Universität Tübingen, Tübingen, Germany
| | - E Nößner
- Immunoanalytics-Tissue control of Immunocytes, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
| | - I Jeremias
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- Department of Gene Vectors, Helmholtz Zentrum München, German Research center for Enviromental Health, Munich, Germany
- Department of Pediatrics, Dr von Hauner Children’s Hospital, LMU Munich, Munich, Germany
| | - W Hiddemann
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - H Leonhardt
- Department of BioIogy II, LMU Munich, Munich, Germany
| | - K Spiekermann
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - M Subklewe
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Translational Cancer Immunology, Gene Center Munich, LMU Munich, Munich, Germany
| | - P A Greif
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
6
|
Hiddemann W, Reincke M. Paraneoplastische Syndrome. Internist (Berl) 2018; 59:113. [DOI: 10.1007/s00108-017-0374-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia 2017:leu2017350. [PMID: 29249818 DOI: 10.1038/leu.2017.350] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Revised: 11/18/2017] [Accepted: 11/23/2017] [Indexed: 11/09/2022]
Abstract
Some patients with acute myeloid leukemia (AML) who are in complete remission after induction chemotherapy harbor persisting pre-leukemic clones, carrying a subset of leukemia-associated somatic mutations. There is conflicting evidence on the prognostic relevance of these clones for AML relapse. Here, we characterized paired pre-treatment and remission samples from 126 AML patients for mutations in 68 leukemia-associated genes. Fifty patients (40%) retained ⩾1 mutation during remission at a variant allele frequency of ⩾2%. Mutation persistence was most frequent in DNMT3A (65% of patients with mutations at diagnosis), SRSF2 (64%), TET2 (55%), and ASXL1 (46%), and significantly associated with older age (P<0.0001) and, in multivariate analyses adjusting for age, genetic risk, and allogeneic transplantation, with inferior relapse-free survival (hazard ratio, 2.34; P=0039) and overall survival (hazard ratio, 2.14; P=036). Patients with persisting mutations had a higher cumulative incidence of relapse before, but not after allogeneic stem cell transplantation. Our work underlines the relevance of mutation persistence during first remission as a novel risk factor in AML. Persistence of pre-leukemic clones may contribute to the inferior outcome of elderly AML patients. Allogeneic transplantation abrogated the increased relapse risk associated with persisting pre-leukemic clones, suggesting that mutation persistence may guide postremission treatment.Leukemia accepted article preview online, 18 December 2017. doi:10.1038/leu.2017.350.
Collapse
Affiliation(s)
- M Rothenberg-Thurley
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - S Amler
- Institute of Biostatistics and Clinical Research, WWU Münster, Münster, Germany
| | - D Goerlich
- Institute of Biostatistics and Clinical Research, WWU Münster, Münster, Germany
| | - T Köhnke
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
| | - N P Konstandin
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
| | - S Schneider
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
| | - M C Sauerland
- Institute of Biostatistics and Clinical Research, WWU Münster, Münster, Germany
| | - T Herold
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
| | - M Hubmann
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
| | - B Ksienzyk
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
| | - E Zellmeier
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
| | - S K Bohlander
- Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
| | - M Subklewe
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - A Faldum
- Institute of Biostatistics and Clinical Research, WWU Münster, Münster, Germany
| | - W Hiddemann
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - J Braess
- Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany
| | - K Spiekermann
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - K H Metzeler
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
8
|
Buerke M, Hasenfuß G, Hiddemann W, Sieber CC. Internistische Notfälle an der Schnittstelle von ambulant und stationär. Internist (Berl) 2017; 58:881-882. [DOI: 10.1007/s00108-017-0304-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
9
|
Trotman J, Barrington S, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson G, Mattiello F, Nielsen T, Sahin D, Hiddemann W, Marcus R, Davies A. PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_20] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J. Trotman
- Haematology Department; Concord Repatriation General Hospital; Sydney Australia
| | - S. Barrington
- KCL and Guys' & St Thomas PET Imaging Centre, Division of Imaging and Biomedical Engineering; Kings College London; London UK
| | - D. Belada
- 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, and Charles University in Prague; Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - M. Meignan
- Service de Médecine Nucléaire; Hôpital Henri Mondor and Université Paris Est Créteil; Créteil France
| | - R. MacEwan
- Cross Cancer Institute; University of Alberta; Edmonton Canada
| | - C. Owen
- Division of Hematology and Hematological Malignancies; Foothills Medical Centre and Tom Baker Cancer Centre; Calgary Canada
| | - V. Ptáčník
- Department of Nuclear Medicine, First Faculty of Medicine; Charles University; Prague Czech Republic
| | - A. Rosta
- Department of Medicine; National Institute of Oncology; Budapest Hungary
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - F. Mattiello
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - D. Sahin
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - W. Hiddemann
- Medical Department III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - R. Marcus
- Department of Haematology; Kings College Hospital; London UK
| | - A. Davies
- Cancer Research UK Centre; University of Southampton; Southampton UK
| |
Collapse
|
10
|
Hoster E, Unterhalt M, Hänel M, Prange-Krex G, Forstpointner R, Florschütz A, Graeven U, Frickhofen N, Wulf G, Lengfelder E, Lerchenmüller C, Schlag R, Dierlamm J, Fischer Von Weikersthal L, Ahmed A, Harich H, Rosenwald A, Klapper W, Dreyling M, Hiddemann W, Herold M. RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_12] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- E. Hoster
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - M. Unterhalt
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - M. Hänel
- Klinik für Innere Medizin III; Klinikum Chemnitz; Chemnitz Germany
| | - G. Prange-Krex
- Innere Medizin, Hämatologie, Onkologie, Gemeinschaftspraxis; Dresden Germany
| | - R. Forstpointner
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - A. Florschütz
- Klinik für Innere Medizin; Städtisches Klinikum Dessau; Dessau Germany
| | - U. Graeven
- Klinik für Hämatologie, Onkologie und Gastroenterologie; Kliniken Maria Hilf; Mönchengladbach Germany
| | - N. Frickhofen
- Klinik Innere Medizin III; HELIOS Dr. Horst Schmidt Kliniken Wiesbaden; Wiesbaden Germany
| | - G. Wulf
- Hämatologie und Medizinische Onkologie; Universitätsmedizin Göttingen; Göttingen Germany
| | - E. Lengfelder
- III. Medizinische Klinik; Klinikum Mannheim; Mannheim Germany
| | | | - R. Schlag
- Innere Medizin, Hämatologie u. Internistische Onkologie; Gemeinschaftspraxis; Würzburg Germany
| | - J. Dierlamm
- II. Medizinischen Klinik und Poliklinik; Universitätsklinikum Eppendorf; Hamburg Germany
| | | | - A. Ahmed
- Medizinische Klinik III; Städtisches Klinikum Braunschweig; Braunschweig Germany
| | - H. Harich
- Onkologie Hof, Medizinisches Versorgungszentrum; Hof Germany
| | - A. Rosenwald
- Institut für Pathologie; Universität Würzburg; Würzburg Germany
| | - W. Klapper
- Sektion Hämatopathologie und Lymphknotenregister; Universitätsklinikum Schleswig-Holstein; Kiel Germany
| | - M. Dreyling
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - W. Hiddemann
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - M. Herold
- Onkologisches Zentrum; HELIOS Klinikum Erfurt; Erfurt Germany
| |
Collapse
|
11
|
Herold M, Hoster E, Janssens A, McCarthy H, Tedeschi A, Pocock C, Rosta A, Schmidt P, Trněný M, Burciu A, Fingerle-Rowson G, Rufibach K, Zeuner H, Hiddemann W, Marcus R. IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_136] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Herold
- Oncology Center, HELIOS-Klinikum Erfurt; Erfurt Germany
| | - E. Hoster
- Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - A. Janssens
- Department of Haematology; UZ Leuven; Leuven Belgium
| | - H. McCarthy
- Department of Haematology; Royal Bournemouth General Hospital; Bournemouth UK
| | - A. Tedeschi
- Division of Hematology; A. O. Ospedale Niguarda Ca’ Granda; Milan Italy
| | - C. Pocock
- Department of Haematology; Kent & Canterbury Hospital; Canterbury UK
| | - A. Rosta
- Department of Haematology, Országos Onkológiai Intézet; Budapest Hungary
| | - P. Schmidt
- Dr. med. Peter Schmidt; Praxis Neunkirchen/Saar Germany
| | - M. Trněný
- 1st Department of Medicine; Charles University General Hospital; Prague Czech Republic
| | - A. Burciu
- Pharma Development Safety and Risk Management; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - K. Rufibach
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - H. Zeuner
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - W. Hiddemann
- Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - R. Marcus
- Department of Haematology; Kings College Hospital; London UK
| |
Collapse
|
12
|
Mottok A, Jurinovic V, Farinha P, Rosenwald A, Ott G, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors J, Sehn L, Gascoyne R, Hoster E, Weigert O, Kridel R. FOXP1
EXPRESSION IS INVERSELY CORRELATED WITH EZH2
MUTATION STATUS AND PREDICTS POOR FAILURE-FREE SURVIVAL IN FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB AND CHEMOTHERAPY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Mottok
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - V. Jurinovic
- Institute for Medical Informatics and Epidemiology; Ludwig Maximilians University; Munich Germany
| | - P. Farinha
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - A. Rosenwald
- Institute of Pathology; University of Würzburg; Würzburg Germany
| | - G. Ott
- Department of Pathology; Robert-Bosch-Hospital; Stuttgart Germany
| | - W. Klapper
- Department of Pathology, Hematopathology Section and Lymph Node Registry; Christian-Albrechts-University Kiel; Kiel Germany
| | - M. Boesl
- Medical Department III; University Hospital of the Ludwig Maximilians University; Munich Germany
| | - W. Hiddemann
- Medical Department III; University Hospital of the Ludwig Maximilians University; Munich Germany
| | - C. Steidl
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - J.M. Connors
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - L.H. Sehn
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - R.D. Gascoyne
- Centre for Lymphoid Cancer; BC Cancer Agency; Vancouver Canada
| | - E. Hoster
- Institute for Medical Informatics and Epidemiology; Ludwig Maximilians University; Munich Germany
| | - O. Weigert
- Medical Department III; University Hospital of the Ludwig Maximilians University; Munich Germany
| | - R. Kridel
- Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre - University Health Network; Toronto Canada
| |
Collapse
|
13
|
Alig S, Jurinovic V, Dreyling M, Pastore A, Kridel R, Gascoyne R, Hiddemann W, Unterhalt M, Hoster E, Weigert O. HIGHER MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_86] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S. Alig
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - V. Jurinovic
- Medical Department III & Institute for Medical Informatics, Biometry and Epidemiology; Ludwig-Maximilians-University; Munich Germany
| | - M. Dreyling
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - A. Pastore
- Human Oncology and Pathogenesis Program; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Kridel
- Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre - University Health Network; Toronto Canada
| | - R. Gascoyne
- Centre for Lymphoid Cancer & Department of Pathology and Laboratory Medicine, BC Cancer Agency; Vancouver Canada
| | - W. Hiddemann
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - M. Unterhalt
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - E. Hoster
- Medical Department III & Institute for Medical Informatics, Biometry and Epidemiology; Ludwig-Maximilians-University; Munich Germany
| | - O. Weigert
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| |
Collapse
|
14
|
Fornecker L, Ou F, Dixon J, Casulo C, Hoster E, Hiddemann W, Sebban C, Morschhauser F, Marcus R, Hochster H, Rummel M, Hagenbeeck A, Kimby E, Herold M, Peterson B, Gyan E, Ladetto M, Zucca E, Nielsen T, Foon K, Vitolo U, Flowers C, Shi Q, Salles G. CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR YOUNG PATIENTS WITH FIRST-LINE FOLLICULAR LYMPHOMA: A POOLED ANALYSIS OF 4249 PATIENTS FROM THE FLASH DATABASE. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_89] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- L. Fornecker
- Department of Hematology; University Hospital of Strasbourg; Strasbourg France
| | - F. Ou
- Division of Biomedical Statistics and Informatics, Mayo Clinic; Rochester USA
| | - J.G. Dixon
- Division of Biomedical Statistics and Informatics, Mayo Clinic; Rochester USA
| | - C. Casulo
- School of Medicine and Dentistry; University of Rochester Medical Center; Rochester USA
| | - E. Hoster
- Department of Internal Medicine III; Ludwig-Maximilians University Hospital, Campus Großhadern; Munich Germany
| | - W. Hiddemann
- Department of Internal Medicine III; Ludwig-Maximilians University Hospital, Campus Großhadern; Munich Germany
| | - C. Sebban
- Onco-Hematology, Centre Leon Berard; University Claude Bernard Lyon 1; Lyon France
| | - F. Morschhauser
- Department of Clinical Hematology; Centre Hospitalier Universitaire, Université de Lille; Lille France
| | - R. Marcus
- Department of Haematology; Addenbrookes Hospital; Cambridge UK
| | - H. Hochster
- Yale Cancer Center; Department of Medicine; New Haven USA
| | - M. Rummel
- Medizinische Klinik IV; University Hospital; Gießen Germany
| | - A. Hagenbeeck
- Department of Hematology; Academic Medical Center; Amsterdam The Netherlands
| | - E. Kimby
- Hematology Centre at Karolinska University Hospital; Karolinska Institutet; Stockholm Sweden
| | - M. Herold
- Department of Hematology and Oncology, HELIOS Klinikum; Erfurt Germany
| | - B.A. Peterson
- Division of Hematology, Oncology and Transplantation; University of Minnesota; Minneapolis USA
| | - E. Gyan
- Department of Hematology and Cell Therapy; University Hospital; Tours France
| | - M. Ladetto
- Department of Hematology, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo; Alessandria Italy
| | - E. Zucca
- Department of Hematology, Oncology Institute of Southern Switzerland (IOSI); Bellinzona Switzerland
| | - T. Nielsen
- Department of Medical Affairs; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - K. Foon
- Department of Medical Affairs, Celgene Corporation; Summit USA
| | - U. Vitolo
- Department of Hematology; Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - C.R. Flowers
- Department of Bone Marrow and Stem Cell Transplantation; Winship Cancer Institute of Emory University; Atlanta USA
| | - Q. Shi
- Division of Biomedical Statistics and Informatics, Mayo Clinic; Rochester USA
| | - G. Salles
- Department of Hematology; Centre Hospitalier Lyon-Sud; Pierre-Benite France
| |
Collapse
|
15
|
Hiddemann W, Barbui A, Canales Albendea M, Cannell P, Collins G, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Tobinai K, Burciu A, Fingerle-Rowson G, Nielsen T, Wolbers M, Marcus R. IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_106] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- W. Hiddemann
- Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - A.M. Barbui
- Department of Hematology; Azienda Ospedaliera Papa Giovanni XXIII; Bergamo Italy
| | | | - P.K. Cannell
- Haematology Department; Fiona Stanley Hospital; Murdoch Australia
| | - G.P. Collins
- Department of Clinical Haematology; Oxford Cancer and Haematology Centre, Churchill Hospital; Oxford UK
| | - J. Dürig
- Medical Faculty (Haematology), Universitaetsklinikum Essen; Essen Germany
| | - R. Forstpointner
- Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - M. Herold
- Oncology Center; HELIOS-Klinikum Erfurt; Erfurt Germany
| | - M. Hertzberg
- Department of Haematology; Prince of Wales Hospital; Sydney Australia
| | - M. Klanova
- 1st Department of Medicine; Charles University General Hospital, Prague, Czech Republic and Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - J.A. Radford
- Manchester Academic Health Science Centre; The University of Manchester and The Christie NHS Foundation Trust; Manchester UK
| | - K. Tobinai
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - A. Burciu
- Pharma Development Safety and Risk Management; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - G.R. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Wolbers
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - R. Marcus
- Department of Haematology; Kings College Hospital; London UK
| |
Collapse
|
16
|
Klapper W, Koch K, Hoster E, Schmitz N, Hiddemann W. Reply to the letter to the editor 'the clinical dilemma of grade 3 follicular lymphoma' by Sorigue et al. Ann Oncol 2016; 27:2303-2304. [PMID: 27502720 DOI: 10.1093/annonc/mdw312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- W Klapper
- Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel
| | - K Koch
- Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel
| | - E Hoster
- Department of Internal Medicine III, University Hospital of Munich, Munich
| | - N Schmitz
- Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Hospital St Georg, Hamburg, Germany
| | - W Hiddemann
- Department of Internal Medicine III, University Hospital of Munich, Munich
| |
Collapse
|
17
|
Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, Hansmann M, Bernd W, Stein H, Pöschel V, Dreyling M, Trümper L, Löffler M, Schmitz N, Hiddemann W, Pfreundschuh M, Klapper W. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol 2016; 27:1323-9. [DOI: 10.1093/annonc/mdw185] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2016] [Accepted: 04/22/2016] [Indexed: 11/14/2022] Open
|
18
|
Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W. Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. Leukemia 2016; 30:1781-4. [PMID: 26965440 DOI: 10.1038/leu.2016.54] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- T Büchner
- Department of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany
| | - U O Krug
- Department of Hematology and Oncology, Klinikum Leverkusen; Leverkusen, Germany
| | - R Peter Gale
- Division of Experimental Medicine, Department of Medicine, Haematology Research Centre, Imperial College London, London, UK
| | - A Heinecke
- Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany
| | - M C Sauerland
- Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany
| | - C Haferlach
- MLL Munich Leukemia Laboratory, Munich, Germany
| | | | - T Haferlach
- MLL Munich Leukemia Laboratory, Munich, Germany
| | - C Müller-Tidow
- Department of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany
| | - M Stelljes
- Department of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany
| | - R M Mesters
- Department of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany
| | - H L Serve
- Department of Hematology and Oncology, University of Frankfurt, Germany
| | - J Braess
- Department of Hematology and Oncology, Krankenhaus Barmherzige Brüder, Regensburg, Germany
| | - K Spiekermann
- Department of Internal Medicine III, University Hospital Munich, Grosshadern, Munich, Germany
| | - P Staib
- Department of Hematology and Oncology, St -Antonius Hospital, Eschweiler, Germany
| | - A Grüneisen
- Department of Hematology and Oncology, Vivantes Clinic Neukölln, Berlin, Germany
| | - A Reichle
- Department of Hematology and Oncology, University Regensburg, Regensburg, Germany
| | - L Balleisen
- Department of Hematology and Oncology, Evangelisches Krankenhaus, Hamm, Germany
| | - H Eimermacher
- Department of Hematology and Oncology, KKH St Marien Hospital, Hagen, Germany
| | - A Giagounidis
- Marienhospital Düsseldorf, Clinic for Oncology, Hematology and Palliative Care, Düsseldorf, Germany
| | - H Rasche
- Department of Hematology and Oncology, Klinikum Bremen-Mitte, Bremen, Germany
| | - E Lengfelder
- Department of Hematology and Oncology, University of Heidelberg, Mannheim, Germany
| | - D Görlich
- Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany
| | - A Faldum
- Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany
| | - W Köpcke
- Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany
| | - R Hehlmann
- Department of Hematology and Oncology, University of Heidelberg, Mannheim, Germany
| | - B J Wörmann
- German Society of Hematology and Oncology, Berlin, Germany
| | - W E Berdel
- Department of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany
| | - W Hiddemann
- Department of Internal Medicine III, University Hospital Munich, Grosshadern, Munich, Germany
| |
Collapse
|
19
|
Hiddemann W. [Malignant lymphomas]. Internist (Berl) 2016; 57:205. [PMID: 26842682 DOI: 10.1007/s00108-016-0018-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- W Hiddemann
- Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81377, München, Deutschland.
| |
Collapse
|
20
|
Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, Klapper W, Engelhard M, Puppe B, Horn H, Staiger AM, Stuhlmann-Laeisz C, Bernd HW, Feller AC, Hummel M, Lenze D, Stein H, Hartmann S, Hansmann ML, Möller P, Hiddemann W, Dreyling M, Ott G, Rosenwald A. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia 2015; 30:854-60. [PMID: 26621338 DOI: 10.1038/leu.2015.330] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Revised: 11/05/2015] [Accepted: 11/13/2015] [Indexed: 01/18/2023]
Abstract
Approximately 15% of follicular lymphomas (FLs) lack breaks in the BCL2 locus. The aim of this study was to better define molecular and clinical features of BCL2-breakpoint/t(14;18)-negative FLs. We studied the presence of BCL2, BCL6 and MYC breaks by fluorescence in situ hybridization and the expression of BCL2, MUM1, CD10, P53 and Ki67 in large clinical trial cohorts of 540 advanced-stage FL cases and 116 early-stage disease FL patients treated with chemotherapy regimens and radiation, respectively. A total of 86% and 53% of advanced- and early-stage FLs were BCL2-breakpoint-positive, respectively. BCL2 was expressed in almost all FLs with BCL2 break and also in 86% and 69% of BCL2-breakpoint-negative advanced- and early-stage FLs, respectively. CD10 expression was significantly reduced in BCL2-breakpoint-negative FLs of all stages and MUM1 and Ki67 expression were significantly increased in BCL2-break-negative early-stage FLs. Patient characteristics did not differ between FLs with and without BCL2 breaks and neither did survival times in advanced-stage FLs. These results suggest that the molecular profile differs to some extent between FLs with and without BCL2 breaks and support the notion that FLs with and without BCL2 breaks belong to the same lymphoma entity.
Collapse
Affiliation(s)
- E Leich
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - E Hoster
- Institute of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany
| | - M Wartenberg
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - M Unterhalt
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - R Siebert
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | - K Koch
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany
| | - W Klapper
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany
| | - M Engelhard
- Department for Radiotherapy, University Hospital Essen, Essen, Germany
| | - B Puppe
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - H Horn
- Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert-Bosch-Krankenhaus, Stuttgart and University of Tübingen, Tübingen, Germany
| | - A M Staiger
- Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert-Bosch-Krankenhaus, Stuttgart and University of Tübingen, Tübingen, Germany
| | - C Stuhlmann-Laeisz
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | - H W Bernd
- Institute of Pathology, University Hospital Schleswig-Holstein, Lübeck, Germany
| | - A C Feller
- Institute of Pathology, University Hospital Schleswig-Holstein, Lübeck, Germany
| | - M Hummel
- Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany
| | - D Lenze
- Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany
| | - H Stein
- Pathodiagnostik Berlin, Berlin, Germany
| | - S Hartmann
- Institute of Pathology, University Hospital Frankfurt am, Frankfurt, Germany
| | - M L Hansmann
- Institute of Pathology, University Hospital Frankfurt am, Frankfurt, Germany
| | - P Möller
- Institute of Pathology, University Hospital Ulm, Ulm, Germany
| | - W Hiddemann
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - M Dreyling
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - G Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
| | - A Rosenwald
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | | |
Collapse
|
21
|
Issels R, Kampmann E, Bücklein V, Nössner E, Lindner L, Schmidt M, Mansmann U, Hiddemann W, Subklewe M, Knösel T. Impact of tumor infiltrating lymphocytes (TILs) on local progression-free (LPFS) and disease-free (DFS) survival in localized high-risk soft tissue sarcoma (HR-STS) after neo-adjuvant chemotherapy (NAC) with regional hyperthermia (RHT). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv513.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Jaeger E, Mumm FH, Laryionava K, Hiddemann W, Heußner P, Winkler EC. P-60 End-of-life decision-making in patients with advanced cancer – a quantitative study of patients’, nurses’ and physicians’ perspectives. BMJ Support Palliat Care 2015. [DOI: 10.1136/bmjspcare-2015-000978.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
23
|
Issels R, Lindner L, Ghadjar P, Reichardt P, Hohenberger P, Verweij J, Abdel-Rahman S, Daugaard S, Salat C, Vujaskovic Z, Wessalowski R, Duerr H, Ploner F, Mella O, Schmidt M, Mansmann U, Jauch K, Belka C, Hiddemann W, Gronchi A. 13LBA Improved overall survival by adding regional hyperthermia to neo-adjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma (HR-STS): Long-term outcomes of the EORTC 62961/ESHO randomized phase III study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(15)30071-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
24
|
Ferrero S, Pastore A, Scholz CW, Forstpointner R, Pezzutto A, Bergmann L, Trümper L, Finke J, Keller U, Ghione P, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M. Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial. Leukemia 2015; 30:984-7. [DOI: 10.1038/leu.2015.215] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
25
|
Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia 2015; 30:484-91. [PMID: 26239198 DOI: 10.1038/leu.2015.214] [Citation(s) in RCA: 185] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Revised: 07/06/2015] [Accepted: 07/10/2015] [Indexed: 12/13/2022]
Abstract
Bispecific T-cell engagers (BiTEs) are very effective in recruiting and activating T cells. We tested the cytotoxicity of the CD33/CD3 BiTE antibody construct AMG 330 on primary acute myeloid leukemia (AML) cells ex vivo and characterized parameters contributing to antileukemic cytolytic activity. The E:T ratio and the CD33 expression level significantly influenced lysis kinetics in long-term cultures of primary AML cells (n=38). AMG 330 induced T-cell-mediated proinflammatory conditions, favoring the upregulation of immune checkpoints on target and effector cells. Although not constitutively expressed at the time of primary diagnosis (n=123), PD-L1 was strongly upregulated on primary AML cells upon AMG 330 addition to ex vivo cultures (n=27, P<0.0001). This phenomenon was cytokine-driven as the sole addition of interferon (IFN)-γ and tumor necrosis factor-α also induced expression. Through blockade of the PD-1/PD-L1 interaction, AMG 330-mediated lysis (n=9, P=0.03), T-cell proliferation (n=9, P=0.01) and IFN-γ secretion (n=8, P=0.008) were significantly enhanced. The combinatorial approach was most beneficial in settings of protracted AML cell lysis. Taken together, we have characterized a critical resistance mechanism employed by primary AML cells under AMG 330-mediated proinflammatory conditions. Our results support the evaluation of checkpoint molecules in upcoming clinical trials with AMG 330 to enhance BiTE antibody construct-mediated cytotoxicity.
Collapse
Affiliation(s)
- C Krupka
- Department of Internal Medicine III, LMU-Klinikum der Universität München, Munich, Germany.,Clinical Co-operation Group Immunotherapy at the Helmholtz Zentrum München, Munich, Germany
| | - P Kufer
- AMGEN Research (Munich) GmbH, Munich, Germany
| | - R Kischel
- AMGEN Research (Munich) GmbH, Munich, Germany
| | - G Zugmaier
- AMGEN Research (Munich) GmbH, Munich, Germany
| | - F S Lichtenegger
- Department of Internal Medicine III, LMU-Klinikum der Universität München, Munich, Germany.,Clinical Co-operation Group Immunotherapy at the Helmholtz Zentrum München, Munich, Germany
| | - T Köhnke
- Department of Internal Medicine III, LMU-Klinikum der Universität München, Munich, Germany.,Clinical Co-operation Group Immunotherapy at the Helmholtz Zentrum München, Munich, Germany
| | - B Vick
- Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - I Jeremias
- Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Oncology, Dr von Haunersches Kinderspital, Ludwig Maximilians-Universität (LMU), Munich, Germany
| | - K H Metzeler
- Department of Internal Medicine III, LMU-Klinikum der Universität München, Munich, Germany
| | - T Altmann
- Department of Internal Medicine III, LMU-Klinikum der Universität München, Munich, Germany.,Clinical Co-operation Group Immunotherapy at the Helmholtz Zentrum München, Munich, Germany
| | - S Schneider
- Department of Internal Medicine III, LMU-Klinikum der Universität München, Munich, Germany
| | - M Fiegl
- Department of Internal Medicine III, LMU-Klinikum der Universität München, Munich, Germany
| | - K Spiekermann
- Department of Internal Medicine III, LMU-Klinikum der Universität München, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - P A Bauerle
- AMGEN Research (Munich) GmbH, Munich, Germany
| | - W Hiddemann
- Department of Internal Medicine III, LMU-Klinikum der Universität München, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - G Riethmüller
- Institute for Immunology, Ludwig-Maximilians-Universität, Munich, Germany
| | - M Subklewe
- Department of Internal Medicine III, LMU-Klinikum der Universität München, Munich, Germany.,Clinical Co-operation Group Immunotherapy at the Helmholtz Zentrum München, Munich, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
26
|
Ponnusamy K, Kohrs N, Ptasinska A, Assi SA, Herold T, Hiddemann W, Lausen J, Bonifer C, Henschler R, Wichmann C. RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1. Oncogenesis 2015; 4:e146. [PMID: 25867177 PMCID: PMC5399174 DOI: 10.1038/oncsis.2015.6] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Revised: 02/08/2015] [Accepted: 02/11/2015] [Indexed: 12/21/2022] Open
Abstract
RUNX1/ETO (RE), the t(8;21)-derived leukemic transcription factor associated with acute myeloid leukemia (AML) development, deregulates genes involved in differentiation, self-renewal and proliferation. In addition, these cells show differences in cellular adhesion behavior whose molecular basis is not well understood. Here, we demonstrate that RE epigenetically silences the gene encoding P-Selectin Glycoprotein Ligand-1 (PSGL-1) and downregulates PSGL-1 expression in human CD34+ and murine lin− hematopoietic progenitor cells. Levels of PSGL-1 inversely and dose-dependently correlate with RE oncogene levels. However, a DNA-binding defective mutant fails to downregulate PSGL-1. We show by ChIP experiments that the PSGL-1 promoter is a direct target of RE and binding is accompanied by high levels of the repressive chromatin mark histone H3K27me3. In t(8;21)+ Kasumi-1 cells, PSGL-1 expression is completely restored at both the mRNA and cell surface protein levels following RE downregulation with short hairpin RNA (shRNA) or RE inhibition with tetramerization-blocking peptides, and at the promoter H3K27me3 is replaced by the activating chromatin mark H3K9ac as well as by RNA polymerase II. Upregulation of PSGL-1 restores the binding of cells to P- and E-selectin and re-establishes myeloid-specific cellular adhesion while it fails to bind to lymphocyte-specific L-selectin. Overall, our data suggest that the RE oncoprotein epigenetically represses PSGL-1 via binding to its promoter region and thus affects the adhesive behavior of t(8;21)+ AML cells.
Collapse
Affiliation(s)
- K Ponnusamy
- 1] Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, Ludwig-Maximilian University Hospital, Munich, Germany [2] Institute of Transfusion Medicine and Immunohematology, Goethe University, Frankfurt, Germany
| | - N Kohrs
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - A Ptasinska
- School of Cancer Sciences, University of Birmingham, Birmingham, UK
| | - S A Assi
- School of Cancer Sciences, University of Birmingham, Birmingham, UK
| | - T Herold
- Department of Internal Medicine 3, Ludwig-Maximilian University Hospital, Munich, Germany
| | - W Hiddemann
- Department of Internal Medicine 3, Ludwig-Maximilian University Hospital, Munich, Germany
| | - J Lausen
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - C Bonifer
- School of Cancer Sciences, University of Birmingham, Birmingham, UK
| | - R Henschler
- 1] Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, Ludwig-Maximilian University Hospital, Munich, Germany [2] Institute of Transfusion Medicine and Immunohematology, Goethe University, Frankfurt, Germany
| | - C Wichmann
- 1] Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, Ludwig-Maximilian University Hospital, Munich, Germany [2] Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| |
Collapse
|
27
|
Zoellner AK, Fritsch S, Prevalsek D, Engel N, Hubmann M, Reibke R, Rieger CT, Hellmuth JC, Haas M, Mumm F, Herold T, Ledderose G, Hiddemann W, Dreyling M, Hausmann A, Tischer J. Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. Bone Marrow Transplant 2015; 50:679-84. [PMID: 25642765 DOI: 10.1038/bmt.2014.328] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Revised: 12/04/2014] [Accepted: 12/17/2014] [Indexed: 01/25/2023]
Abstract
Prognosis is poor for patients with biologically aggressive Non-Hodgkin lymphoma (NHL), refractory to chemotherapy or relapsed after autologous transplantation, especially when no disease control before allogeneic transplantation is achieved. In 16 patients (median age 53, median prior regimes 5) with relapsed or refractory non-remission NHL, we analysed retrospectively the efficacy of a sequential therapy comprising clofarabine re-induction followed by a reduced-intensity conditioning with fludarabine, CY and melphalan, and T-cell-replete HLA-haploidentical transplantation. High-dose CY was utilized post-transplantation. All patients engrafted. Early response (day +30) was achieved in 94%. Treatment-related grade III-IV toxicity occurred in 56%, most commonly transient elevation of transaminases (36%), while there was a low incidence of infections (19% CMV reactivation, 19% invasive fungal infection) and GVHD (GVHD: acute III-IV: 6%; mild chronic: 25%). One-year non-relapse mortality was 19%. After a median follow-up of 21 months, estimated 1- and 2-year PFS was 56 and 50%, respectively, with 11 patients (69%) still alive after 2 years. In summary, sequential therapy is feasible and effective and provides an acceptable toxicity profile in high-risk non-remission NHL. Presumably, cytotoxic reinduction with clofarabine provides enough remission time for the graft-versus lymphoma effect of HLA-haploidentical transplantation to kick in, even in lymphomas that are otherwise chemo-refractory.
Collapse
Affiliation(s)
- A-K Zoellner
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - S Fritsch
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - D Prevalsek
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - N Engel
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - M Hubmann
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - R Reibke
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - C T Rieger
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - J C Hellmuth
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - M Haas
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - F Mumm
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - T Herold
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - G Ledderose
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - W Hiddemann
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - M Dreyling
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| | - A Hausmann
- 1] Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany [2] Department I of Internal Medicine, Klinikum München-Schwabing, Munich, Germany
| | - J Tischer
- Ludwig-Maximilians-University Hospital of Munich-Grosshadern, Department III of Internal Medicine, Hematopoietic Stem Cell Transplantation, Munich, Germany
| |
Collapse
|
28
|
Abstract
Increasing numbers of therapeutic options are becoming available for the systemic treatment of metastasized colorectal cancer (mCRC) which emphasizes the need for strategic decision making and planning across multiple lines of treatment. The choice of first-line therapy is influenced by clinical and molecular characteristics of patients and tumors, such as (K-)RAS gene mutations with respect to therapy guidance of epidermal growth factor receptor (EGFR) antibodies. First-line therapy is the major determinant of subsequent treatment regimens and can therefore be considered as the key decision in patients with mCRC. The German standard for first-line therapy in the majority of patients includes chemotherapy in combination with biological agents, with antibodies targeting EGFR possibly being the preferable option in patients with (K-)RAS wild-type tumors. The development of effective therapeutic strategies in patients with (K-)RAS mutant mCRC tumors must be promoted in the future and requires intensive research because the therapy options for this group of patients are very limited.
Collapse
Affiliation(s)
- D P Modest
- Medizinische Klinik und Poliklinik III & Comprehensive Cancer Center, Klinikum der Universität München, Marchioninistr. 15, 81377, München, Deutschland,
| | | | | |
Collapse
|
29
|
Michl M, Holtzem B, Koch J, Moosmann N, Holch J, Hiddemann W, Heinemann V. [Metastatic colorectal cancer--analysis of treatment modalities and survival now and then]. Dtsch Med Wochenschr 2014; 139:2068-72. [PMID: 25268205 DOI: 10.1055/s-0034-1387283] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND AND AIM In metastatic colorectal cancer (mCRC) available systemic treatment options substantially increased in the last decades. Nowadays, overall survival in mCRC patients ranges from 25 to 35 months as recent studies report. We compared treatment modalities and survival in mCRC patients who were treated at our center in two different periods. PATIENTS AND METHODS Within two sequential monocentric analyses patients with mCRC treated at our Comprehensive Cancer Center (CCC) between 07/1994 and 10/2007 (cohort 1) and from 11/2007 to 05/2010 (cohort 2) were evaluated for applied treatment, for best response to treatment and for survival (OS). For statistical analysis the Kaplan-Meier estimator was used. RESULTS Both patient cohorts showed comparable characteristics regarding median age (63 vs. 64 yrs), localization of primary tumor (colon 60% vs. rectum 40%) and number and site of distant metastasis (1 site [75%] vs. ≥ 2 site [25%]; liver-only metastasis [55%]). About half of all patients in each cohort received at least three consecutive chemotherapy regimens. In cohort 1, treatment mainly consisted of chemotherapy alone (>80%), whereas in cohort 2 chemotherapy was combined with a monoclonal antibody in nearly 70%. Rate of surgical resection of metastasis increased over time (8% vs. 17%). Median OS was 27.3 months (cohort 1) vs. 39.4 months (cohort 2). CONCLUSION The increasing availability of effective substances including monoclonal antibodies and individual approaches including secondary surgery of distant metastasis might explain that survival in pts with mCRC has substantially improved over the last decades.
Collapse
Affiliation(s)
- M Michl
- Medizinische Klinik und Poliklinik III, CCC - Comprehensive Cancer Center, Klinikum der Ludwig-Maximilians-Universität München, Standort Großhadern
| | - B Holtzem
- Medizinische Klinik und Poliklinik III, CCC - Comprehensive Cancer Center, Klinikum der Ludwig-Maximilians-Universität München, Standort Großhadern
| | - J Koch
- Medizinische Klinik und Poliklinik III, CCC - Comprehensive Cancer Center, Klinikum der Ludwig-Maximilians-Universität München, Standort Großhadern
| | - N Moosmann
- Medizinische Klinik und Poliklinik III, CCC - Comprehensive Cancer Center, Klinikum der Ludwig-Maximilians-Universität München, Standort Großhadern
| | - J Holch
- Medizinische Klinik und Poliklinik III, CCC - Comprehensive Cancer Center, Klinikum der Ludwig-Maximilians-Universität München, Standort Großhadern
| | - W Hiddemann
- Medizinische Klinik und Poliklinik III, CCC - Comprehensive Cancer Center, Klinikum der Ludwig-Maximilians-Universität München, Standort Großhadern
| | - V Heinemann
- Medizinische Klinik und Poliklinik III, CCC - Comprehensive Cancer Center, Klinikum der Ludwig-Maximilians-Universität München, Standort Großhadern
| |
Collapse
|
30
|
Schnaiter A, Hiddemann W. [Symptomatic therapy of SIADH in small cell lung cancer by tolvaptan]. Dtsch Med Wochenschr 2014; 139:2077-9. [PMID: 25268207 DOI: 10.1055/s-0034-1387289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
HISTORY AND CLINICAL FINDINGS A 69-year-old woman with small cell lung cancer presented in the emergency ward because of severe back pain. She had received tolvaptan treatment in hospital for paraneoplastic SIADH but had discontinued the drug after discharge from hospital 3 days ago. Restriction of fluid intake was not tolerated. INVESTIGATIONS Consistent with SIADH, there were profound hyponatraemia, elevated urine osmolality and urine sodium. TREATMENT AND COURSE After a generalized seizure triggered by hyponatraemia, tolvaptan was reintroduced in addition to radiochemotherapy. Serum sodium concentration increased and finally returned to normal. CONCLUSION If restriction of fluid intake is not tolerated by the patients the vasopressin antagonist tolvaptan provides an alternative symptomatic treatment of paraneoplastic SIADH.
Collapse
Affiliation(s)
- A Schnaiter
- Medizinische Klinik und Poliklinik III, Klinikum der Universität München
| | - W Hiddemann
- Medizinische Klinik und Poliklinik III, Klinikum der Universität München
| |
Collapse
|
31
|
Bokemeyer C, Hiddemann W. Moderne Krebstherapie: aktueller Stand und zukünftige Entwicklung. Dtsch Med Wochenschr 2014; 139:2067. [DOI: 10.1055/s-0034-1387350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- C. Bokemeyer
- II. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf
| | - W. Hiddemann
- III. Medizinische Klinik und Poliklinik, Klinikum der Universität München, Campus Großhadern
| |
Collapse
|
32
|
Laryionava K, Heußner P, Hiddemann W, Winkler EC. Framework for timing of the discussion about forgoing cancer-specific treatment based on a qualitative study with oncologists. Support Care Cancer 2014; 23:715-21. [PMID: 25172311 DOI: 10.1007/s00520-014-2416-8] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2014] [Accepted: 08/18/2014] [Indexed: 11/28/2022]
Abstract
BACKGROUND Many patients with advanced cancer receive aggressive chemotherapy close to death and are referred too late to palliative or hospice care. AIM The aim of this study was to investigate oncologists' and oncology nurses' perceptions of the optimal timing for discussions about forgoing cancer-specific therapy at the End-of-Life (EOL) and the reasons that might hinder them. DESIGN Qualitative in-depth interviews with oncologists and oncology nurses were carried out. The empirical data were evaluated from a normative perspective. SETTING/PARTICIPANTS Twenty-nine physicians and nurses working at the Department of Hematology and Oncology of a German university hospital were interviewed. RESULTS Health-care professionals differed considerably in their understanding of when to initiate discussions about forgoing cancer-specific therapy at the EOL. However, their views could be consolidated into three approaches: (1) preparing patients gradually throughout the course of disease (anticipatory approach) which is best suited to empower patient self-determination in decision-making, (2) waiting until the patient him/herself starts the discussion about forgoing cancer-specific treatment, and (3) waiting until all tumor-specific therapeutic options are exhausted. CONCLUSION The empirically informed ethical analysis clearly favors an approach that prepares patients for forgoing cancer-specific therapy throughout the course of disease. Since the last two approaches often preclude advance care planning, these approaches may be less ethically acceptable. The proposed framework could serve as a starting point for the development of concrete recommendations on the optimal timing for EOL discussions.
Collapse
Affiliation(s)
- K Laryionava
- Department of Medical Oncology, National Center for Tumor Diseases (NCT), Programme for Ethics and Patient-oriented Care, Heidelberg University Hospital , Im Neuenheimer Feld 460, 69120, Heidelberg, Germany,
| | | | | | | |
Collapse
|
33
|
Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlüter M, Draenert R, Hiddemann W, Subklewe M. P20. Lack of T cell exhaustion in acute myeloid leukaemia. J Immunother Cancer 2014. [PMCID: PMC4072134 DOI: 10.1186/2051-1426-2-s2-p11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
34
|
Lichtenegger FS, Beck B, Bigalke I, Geiger C, Hiddemann W, Henschler R, Kvalheim G, Schendel DJ, Subklewe M. P55. Dendritic cell vaccination for postremission therapy in AML. J Immunother Cancer 2014. [PMCID: PMC4072282 DOI: 10.1186/2051-1426-2-s2-p29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
35
|
Abstract
Major changes have taken place within the last few years in the management of follicular lymphoma (FL) leading to substantial improvement in prognosis and overall survival. For some patients with limited disease stages I and II, radiotherapy may be associated with durable responses; however, it is unclear whether patients are cured and new approaches such as the combination of irradiation with rituximab or even single-agent rituximab need to be explored. Whereas watch and wait is the current standard for stage III and IV disease with low tumour burden, better indices are warranted to potentially select patients for whom early intervention is preferred. For advanced stages with a high tumour burden, immunochemotherapy followed by 2 years of rituximab maintenance is widely accepted as standard therapy, although re-treatment at recurrence may be an alternative option. Highly attractive new therapeutic options have recently arisen from new antibodies, and from new agents targeting oncogenic pathways such as B-cell receptor signalling pathways or inhibition of bcl 2. Furthermore, immunomodulatory drugs may add to the therapeutic armamentarium and may lead to 'chemotherapy-free' therapies in the near future. Hence, the management of FLs has become a moving target and the hope is justified that the long-term perspectives of patients suffering from the disease will be further improved in the near future.
Collapse
Affiliation(s)
- W Hiddemann
- Department of Internal Medicine III, University of Munich, Campus Großhadern, Munich, Germany
| | - B D Cheson
- Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA
| |
Collapse
|
36
|
Greil R, Hiddemann W. Erfolgreiche Krebsbehandlung: Chancen und Herausforderungen. Dtsch Med Wochenschr 2013; 138:2083. [DOI: 10.1055/s-0033-1349623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- R. Greil
- Universitätsklinik für Innere Medizin III mit Hämatologie, Internistischer Onkologie, Hämostaseologie, Infektiologie und Rheumatologie, Onkologisches Zentrum, Landeskrankenhaus Salzburg
| | - W. Hiddemann
- Medizinische Klinik und Poliklinik III, Klinikum der Universität München
| |
Collapse
|
37
|
Abstract
Acquired inhibitors of coagulation cause a life-threatening disease. Clinically newly occurring hemorrhagic diathesis combined with prolonged activated partial thromboplastin time (aPTT) time is diagnostically indicative and can be confirmed by a positive plasma exchange test. For thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP-HUS) the diagnosis of Coombs negative hemolytic anemia together with thrombocytopenia should lead to the detection of fragmentocytes in peripheral blood smears. Hairy cell leukemia is a rare subgroup of chronic B-cell neoplasia with the clinical signs of pancytopenia and splenomegaly which characteristically stain positive for CD103. The gastrointestinal stromal tumor (GIST) has nothing in common with classical soft tissue sarcoma based on the activating mutation of the KIT or PDGFRA gene (positivity for CD117). In all of these disorders the correct diagnosis has a major influence on patient outcome. For the case of acquired inhibitors of coagulation immunosuppressive therapy and substitution of coagulation factors (e.g. recombinant factor VIIa) or for TTP-HUS the immediate start of plasma exchange are mandatory. For hairy cell leukemia a very effective treatment exists with purine analogs (e.g. cladribine) and for metastatic inoperable GIST with tyrosine kinase inhibitors (e.g. imatinib).
Collapse
Affiliation(s)
- L H Lindner
- Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, 81377, München, Deutschland,
| | | |
Collapse
|
38
|
Hiddemann W, Reiser M. Rationale Bildgebung in der Inneren Medizin. Internist (Berl) 2013; 54:789. [DOI: 10.1007/s00108-012-3168-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Hiddemann W. AML: Kolonie-stimulierende Faktoren auf dem Prüfstand. Dtsch Med Wochenschr 2012; 137:2306. [DOI: 10.1055/s-0032-1330135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
40
|
Hegerl U, Heussner P, Hiddemann W. [Psychological disorders in internal medicine]. Internist (Berl) 2012; 53:1269-70. [PMID: 23052324 DOI: 10.1007/s00108-011-2993-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- U Hegerl
- Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Leipzig, Deutschland
| | | | | |
Collapse
|
41
|
|
42
|
Hiddemann W. „Watch and wait“ bei follikulären Lymphomen – Zeit für einen Strategiewechsel? Dtsch Med Wochenschr 2012; 137:2181-2. [DOI: 10.1055/s-0032-1305316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- W. Hiddemann
- Medizinische Klinik und Poliklinik III, Klinikum der Universität München
| |
Collapse
|
43
|
Heidemann E, Hiddemann W. Aktuelle Diagnostik und Behandlung in Hämatologie und Onkologie. Dtsch Med Wochenschr 2012; 137:2141. [DOI: 10.1055/s-0032-1327228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- E. Heidemann
- Onkologischer Schwerpunkt Stuttgart, Medizinische Klinik, Diakonie-Klinikum Stuttgart
| | - W. Hiddemann
- Medizinische Klinik III, Klinikum der Universität München
| |
Collapse
|
44
|
Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367:520-31. [PMID: 22873532 DOI: 10.1056/nejmoa1200920] [Citation(s) in RCA: 361] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission. METHODS We randomly assigned patients 60 years of age or older with mantle-cell lymphoma, stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabine, and cyclophosphamide (R-FC) every 28 days or to eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days. Patients who had a response underwent a second randomization to maintenance therapy with rituximab or interferon alfa, each given until progression. RESULTS Of the 560 patients enrolled, 532 were included in the intention-to-treat analysis for response, and 485 in the primary analysis for response. The median age was 70 years. Although complete-remission rates were similar with R-FC and R-CHOP (40% and 34%, respectively; P=0.10), progressive disease was more frequent with R-FC (14%, vs. 5% with R-CHOP). Overall survival was significantly shorter with R-FC than with R-CHOP (4-year survival rate, 47% vs. 62%; P=0.005), and more patients in the R-FC group died during the first remission (10% vs. 4%). Hematologic toxic effects occurred more frequently in the R-FC group than in the R-CHOP group, but the frequency of grade 3 or 4 infections was balanced (17% and 14%, respectively). In 274 of the 316 patients who were randomly assigned to maintenance therapy, rituximab reduced the risk of progression or death by 45% (in remission after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% confidence interval, 0.36 to 0.87; P=0.01). Among patients who had a response to R-CHOP, maintenance therapy with rituximab significantly improved overall survival (4-year survival rate, 87%, vs. 63% with interferon alfa; P=0.005). CONCLUSIONS R-CHOP induction followed by maintenance therapy with rituximab is effective for older patients with mantle-cell lymphoma. (Funded by the European Commission and others; ClinicalTrials.gov number, NCT00209209.).
Collapse
Affiliation(s)
- H C Kluin-Nelemans
- Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
|
46
|
Hutter G, Zimmermann Y, Rieken M, Hartmann E, Rosenwald A, Hiddemann W, Dreyling M. Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL. Leukemia 2012; 26:2442-4. [DOI: 10.1038/leu.2012.118] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
47
|
Hauke D, Reiter-Theil S, Hoster E, Hiddemann W, Winkler E. The role of relatives in decisions concerning life-prolonging treatment in patients with end-stage malignant disorders: informants, advocates or surrogate decision-makers? Ann Oncol 2011; 22:2667-2674. [DOI: 10.1093/annonc/mdr019] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Hiddemann W. [Adult non-hodgkin lymphoma: Has high-dose chemotherapy improved the prognosis?]. Dtsch Med Wochenschr 2011; 136:2293. [PMID: 22052589 DOI: 10.1055/s-0031-1292060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Affiliation(s)
- W Hiddemann
- Klinikum der Universität, München-Großhadern
| |
Collapse
|
49
|
Deshpande AJ, Rouhi A, Lin Y, Stadler C, Greif PA, Arseni N, Opatz S, Quintanilla-Fend L, Holzmann K, Hiddemann W, Döhner K, Döhner H, Xu G, Armstrong SA, Bohlander SK, Buske C. The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia 2011; 25:1718-27. [PMID: 21681188 DOI: 10.1038/leu.2011.153] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The t(10;11)(p13-14;q14-21) translocation, giving rise to the CALM-AF10 fusion gene, is a recurrent chromosomal rearrangement observed in patients with poor prognosis acute myeloid leukemia (AML). Although splicing of the CALM-AF10 fusion transcripts has been described in AML patients, the contribution of different CALM and AF10 domains to in vivo leukemogenesis remains to be defined. We therefore performed detailed structure-function studies of the CALM-AF10 fusion protein. We demonstrate that fusion of the C-terminal 248 amino acids of CALM, which include the clathrin-binding domain, to the octapeptide motif-leucine-zipper (OM-LZ) domain of AF10 generated a fusion protein (termed CALM-AF10 minimal fusion (MF)), with strikingly enhanced transformation capabilities in colony assays, providing an efficient system for the expeditious assessment of CALM-AF10-mediated transformation. Leukemias induced by the CALM-AF10 (MF) mutant recapitulated multiple aspects of full-length CALM-AF10-induced leukemia, including aberrant Hoxa cluster upregulation, a characteristic molecular lesion of CALM-AF10 leukemias. In summary, this study indicates that collaboration of the clathrin-binding and the OM-LZ domains of CALM-AF10 is sufficient to induce AML. These findings further suggest that future approaches to antagonize CALM-AF10-induced transformation should incorporate strategies, which aim at blocking these key domains.
Collapse
Affiliation(s)
- A J Deshpande
- Department of Medicine III, Klinikum Grosshadern, Munich, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Herold T, Jurinovic V, Metzeler KH, Boulesteix AL, Bergmann M, Seiler T, Mulaw M, Thoene S, Dufour A, Pasalic Z, Schmidberger M, Schmidt M, Schneider S, Kakadia PM, Feuring-Buske M, Braess J, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Bohlander SK. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 2011; 25:1639-45. [PMID: 21625232 DOI: 10.1038/leu.2011.125] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|